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Abstract
Background and Aims: Inflammatory bowel disease [IBD] is associated with a 1.5- to 3-fold 
increased risk of venous thromboembolism [VTE] events. The aim of this study was to determine 
the risk of VTE in IBD as a complication of systemic corticosteroids and anti-tumour necrosis factor 
alpha [TNFα] therapies.
Methods: A systematic review and meta-analysis was conducted, which conforms to the Preferred 
Reporting Items for Systematic Reviews and Meta-analyses [PRISMA] statement. PubMed, 
EMBASE, Cochrane Library and Web of Science were searched for English-language studies 
published from inception inclusive of 15 April 2017. The population-intervention-comparison-
outcome [PICO] format and statistically the random-effects and fixed-effect models were used 
to compare VTE risk during steroid and anti-TNFα treatment. Quality of the included studies was 
assessed using the Newcastle–Ottawa scale. The PROSPERO registration number is 42017070084.
Results: We identified 817 records, of which eight observational studies, involving 58 518 IBD 
patients, were eligible for quantitative synthesis. In total, 3260 thromboembolic events occurred. 
Systemic corticosteroids were associated with a significantly higher rate of VTE complication 
in IBD patients as compared to IBD patients without steroid medication (odds ratio [OR]: 2.202; 
95% confidence interval [CI]: 1.698–2.856, p < 0.001). In contrast, treatment with anti-TNFα agents 
resulted in a 5-fold decreased risk of VTE compared to steroid medication [OR: 0.267; 95% CI: 
0.106–0.674, p = 0.005].
Conclusion: VTE risk should be carefully assessed and considered when deciding between anti-
TNFα and steroids in the management of severe flare-ups. Thromboprophylaxis guidelines should 
be followed, no matter the therapy choice.
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1. Introduction
Venous thromboembolism [VTE], mainly deep vein thrombosis 
[DVT] and pulmonary embolism [PE], is one of the most common 
types of cardiovascular disorders. VTE is associated with several ad-
verse consequences including increased morbidity and mortality.1 
The incidence rate of the first VTE event is approximately 1:1000/
year in the United States.2,3 Despite adequate anticoagulant therapy, 
recurrent VTE occurs frequently in the first few months.2,3 The 
long-term complications of VTE, such as post-thrombotic syndrome 
or chronic thromboembolic pulmonary hypertension, also signifi-
cantly reduce the patient’s quality of life.4
The risk of VTE has been widely examined in inflammatory 
bowel disease [IBD] patients, including ulcerative colitis [UC] and 
Crohn’s disease [CD].5 Several population-based cohort studies have 
shown that IBD patients have a 1.5- to 3-fold higher risk of develop-
ing VTE compared to non-IBD controls.6–10 In a recent meta-analysis, 
Yuhara et al. estimated the relative risk [RR] for DVT and PE among 
IBD patients to be 2.20 (95% confidence interval [CI]: 1.83–2.65).8 
The risk of VTE in IBD patients is increased regardless of the diag-
nosis [UC: RR = 2.57, 95% CI: 2.02–3.28; CD: RR = 2.12, 95% CI: 
1.40–3.20]8 and sex.5,8,10
The pathogenesis of VTE in IBD patients is multifactorial and 
not completely understood. Inherited risk factors for VTE, such as 
factor V Leiden, factor II prothrombin, factor XIII, plasminogen ac-
tivator inhibitor type 1, methylenetetrahydrofolate reductase gene 
polymorphism, antithrombin deficiency, protein C/protein S defi-
ciencies, hyperhomocysteinaemia and dysfibrinogenaemia, also play 
a role in IBD-VTE. However, these hereditary risk factors contribute 
equally to VTE in patients with IBD compared to VTE in the general 
population.11,12
Indeed, acquired risk factors appear the most relevant ones 
in the development of VTE in IBD patients.13 The majority of 
VTE occurs during the acute flare-up of the disease [hazard risk 
(HR) = 8.4, 95% CI: 5.5–12.8], compared with periods of clinical 
remission [HR = 2.1, 95% CI: 1.6–2.9].14,15 Moreover, hospitalized 
IBD patients have higher rates of VTE than non-IBD hospitalized 
patients.6,14,16–20 The well-established, non-specific acquired VTE risk 
factors (e.g. smoking, oral contraceptives, immobilization, central 
venous catheters, pregnancy and dehydration) might also provoke 
the development of VTE in IBD patients.13,15
To date, most studies have suggested that IBD is associated with 
prothrombotic abnormalities, including activation of the coagula-
tion cascade, downregulation of its natural inhibitors and impair-
ment of fibrinolysis.21 Increased platelet count and dysfunction of the 
endothelium also contribute to VTE in IBD patients. Inflammatory 
mediators, such as tumour necrosis factor alpha [TNFα], CD40 
ligand [CD40L], interleukin-6 [IL-6], interleukin-1 [IL-1] and 
C-reactive protein [CRP], have been shown to lead to activation of 
coagulation.13
Some drugs used in IBD treatment were found to influence 
the haemostatic system. Among them, glucocorticoids are potent 
anti-inflammatory drugs widely used for the induction of remission 
during the acute phase of IBD. Experimental studies have shown that 
glucocorticoid treatment alone increases the levels of clotting factors 
and fibrinogen.22
However, conflicting data exist regarding the association between 
coagulation and anti-TNFα treatment. Anti-TNFα agents can be 
used for induction and maintenance of remission in IBD. Increased 
TNFα levels in IBD seem to be a disease-specific risk factor for accel-
erated thrombus formation, and thus therapies antagonizing TNFα 
potentially decrease the risk for thromboembolic complications. 
In a prospective observational cohort study in rheumatoid arth-
ritis patients, use of anti-TNFα therapy was not associated with an 
increased risk of VTE.23 In contrast to these findings, retrospective 
data from the French adverse drug reporting system suggested that 
VTE could be favoured by TNFα blockers.24 Moreover, the forma-
tion of antiphospholipid antibodies during anti-TNFα treatment 
could promote hypercoagulation state in IBD patients.25
Therapy-specific risk factors for IBD, such as the effects of steroid 
treatment and anti-TNFα treatment on VTE complications, have not 
been compared in previous meta-analyses. Therefore, our primary 
objective was to determine whether corticosteroid and anti-TNFα 
treatment carry an increased risk of venous thromboembolic com-
plication in IBD flare-ups.
2. Methods
The protocol of this systematic review and meta-analysis is in accord-
ance with the Preferred Reporting Items for Systematic Reviews 
and Meta-analyses [PRISMA] statement26 and the Meta-analysis 
Of Observational Studies in Epidemiology [MOOSE] Statement27 
[Supplementary Tables S1 and S2, respectively].
Details of the protocol for this systematic review were registered 
on the International Prospective Register of Systematic Reviews 
[PROSPERO] and can be accessed at www.crd.york.ac.uk/
PROSPERO/display_record.asp?ID=CRD42017070084.
2.1. Eligibility criteria
Observational studies evaluating venous thromboembolic complica-
tions in patients with CD or UC requiring systemic corticosteroid 
or anti-TNFα therapy for flare-up of their disease were eligible for 
inclusion [Table 1]. In our meta-analysis, patients were divided into 
two subgroups, as follows: (A) steroid therapy vs treatment without 
steroids and (B) anti-TNFα vs steroid treatment. First, we selected 
studies that reported data on steroid vs no steroid treatment in IBD 
patients during hospitalization, within 3  months after discharge28 
or in a postoperative setting.20,29,30 Publications for which data were 
retrieved from national registries31 or inception cohorts32 were also 
included. In the second part of the analysis we examined correlations 
between studies investigating VTE complications on anti-TNFα 
treatment or steroid therapy for active disease.28,33,34 Studies evaluat-
ing only paediatric patients [age < 18 years] were excluded.
2.2. Search strategy
An electronic literature search was conducted until 15 April 2017 
using PubMed [http://www.ncbi.nlm.nih.gov/pubmed], EMBASE 
[https://www.embase.com], Cochrane Library [http://www.
Table 1. Eligibility criteria
Eligibility criteria
Observational studies
Adults (aged ≥ 18 years)
English language papers
Inflammatory bowel disease patients: Crohn’s disease, ulcerative colitis
Patients with venous/pulmonary thromboembolism
Compared steroid therapy* with no steroid treatmenta
Compared anti-TNFα therapy with steroid treatmentb
aFor the analysis of steroid effect on venous thromboembolism.
bFor the analysis of anti-TNFα effect on venous thromboembolism.
*Systemic prednisolone, methylprednisolone.
490 P. Sarlos et al.
Downloaded from https://academic.oup.com/ecco-jcc/article-abstract/12/4/489/4694102
by Hungary EISZ Consortium user
on 13 April 2018
cochranelibrary.com] and Web of Science [www.webofknowledge.
com]. Key questions were formulated according to the ‘PICO’ 
method. P [population]: patients diagnosed with IBD; I  [interven-
tion]: drugs used for IBD treatment: systemic steroid usage in sub-
group A; TNFα inhibitor therapy in subgroup B; C [comparator]: no 
steroid treatment compared with steroid therapy, steroid therapy as 
a comparator for TNFα inhibitors; O [outcome]: venous thrombo-
embolism. To the best of our knowledge, no study assessing the risk 
of thromboembolism during anti-TNFα treatment compared to pla-
cebo exists.
The following medical subject headings [MeSH] and/or free text 
terms were searched: ‘venous thromboembolism’, ‘deep vein throm-
bosis’, ‘pulmonary embolism’ combined with ‘inflammatory bowel 
disease’, ‘ulcerative colitis’, ‘Crohn’s disease’ and ‘systemic corticos-
teroids’ and ‘steroids’. Data were collected from inception up to 15 
April 2017. In addition, the reference lists of relevant articles were 
scanned. Duplicate publications were excluded. The literature search 
was limited to English-language papers.
2.3. Study selection and data collection process
After database searches, one author [KSz] removed duplicates using 
reference manager software [EndNote X8, Clarivate Analytics]. The 
titles of articles and abstracts were initially screened by two authors 
[PS and KSz] independently and relevant articles were shortlisted. 
Full texts of the remaining articles were screened by two authors 
[PS and KSz] against the inclusion criteria [Table 1]. Discrepancies 
were resolved by consensus. A third person [PH] was involved when 
necessary. Case reports, letters and reviews were excluded from the 
quantitative synthesis. Additionally, studies lacking adequate data 
(without calculated odds ratio [OR]) or without extractable data 
were eliminated.
The following data were extracted from each included study: first 
author, year of publication, study design [prospective/retrospective 
and single-centre/multi-centre study], inclusion period, type of dis-
ease [CD or UC], country/geographical region of origin, study popu-
lation, age range of study subjects, number of total IBD patients 
[subdivided into CD and UC groups], number of VTE events in 
IBD cases, and number of VTE events in IBD cases [controls]. The 
number of patients on steroid or TNFα inhibitor therapy was also 
recorded when it was available.
2.4. Study quality and risk of bias
The quality and biases of the studies included in the analysis were 
assessed using a modified Newcastle–Ottawa scale [NOS] for obser-
vational studies in meta-analyses.35 Two reviewers [NF and PS] inde-
pendently evaluated the quality of each included study, discrepancies 
were discussed and if consensus was not reached, a third reviewer 
was consulted [PH]. The NOS scale for cohort studies contains 
eight items covering three main domains [selection, comparability 
and outcome]. A study can be awarded a maximum of one star for 
each numbered item; on the other hand, a maximum of two stars 
can be given for comparability. Each item was rated as ‘high risk’ 
[zero stars], ‘low risk’ [one star] or ‘unclear risk’ [zero stars] cor-
responding to the definitions [Supplementary Table S3]. The item 
‘Demonstration that outcome of interest was not present at start of 
study’ was not applicable because patients not exhibiting symptoms 
for VTE are not routinely tested in daily clinical practice. The last 
item in the outcome domain [‘Adequacy of follow-up of cohorts’] 
was also removed from the tool because it is uninterpretable in retro-
spective studies.
2.5. Outcome assessment
The main outcome studied in this meta-analysis was the chance of 
VTE occurrence in two patient groups: (A) steroid vs no steroid 
treatment group, (B) anti-TNFα vs steroid treatment group. If there 
were not sufficient data published to assess the risk for VTE in IBD 
patients [e.g. no OR calculated or insufficient data for calculating 
OR], the article was excluded from the meta-analysis.
2.6. Statistical data analysis
For our outcome data of VTE events from the individual studies we 
extracted the OR and its 95% CI. OR or CI were calculated from the 
original data, when these parameters were not specified.28,31 In the 
study of Ananthakrishnan et al.,33 we used HR rather than convert-
ing it to OR. In the literature, there are methods for the conversion 
of HR to OR,36,37 but this transaction carries bias. Only three articles 
were identified where the TNFα inhibitor and the steroid treatment 
were compared. A meta-analysis including few studies bears greater 
publication bias and we did not want to increase the chance for 
errors with this conversion. The follow-up times in the studies were 
nearly the same, and in these cases, the HR can be handled as OR in 
a forest plot according to Cochran’s Handbook [Chapter 9].38
The meta-analytic calculations were performed by Comprehensive 
MetaAnalysis software [Version3, Biostat Inc.]. Heterogeneity was 
tested by using Cochrane’s Q and I2 statistics, where I2 = 100% × 
(Q−df)/Q and represents the magnitude of the heterogeneity [mod-
erate: 30–60%, substantial: 50–90%, considerable: 75–100%]. 
In our study, as seen in Figure  2A, Q  =  18.166, p  =  0.006 and 
I2 = 66.971, and thus we applied the random-effects model, using the 
DerSimonian–Laird method.39 In Figure 2B, Peto’s methods [fixed-
effects model] were used, because the results of the tests [Q = 1.486, 
p = 0.476, I2 = 0.000%] indicated a homogenous dataset.40
Publication bias was evaluated by visual assessment of the fun-
nel plot because only six studies were included in our meta-analysis 
[subgroup A]. Tests for funnel plot asymmetry should be used only 
when there are at least ten studies included in the meta-analysis, be-
cause the power of the test is too low to distinguish chance from real 
asymmetry when the number of studies is less than ten.38
3. Results
3.1. Literature search results
Our systematic literature search strategy identified 817 potentially 
relevant records [PRISMA flow diagram; Figure 1]. After removal 
of duplicates and screening of title and abstract, 21 papers remained 
for full-text evaluation. Following the revision of the eligible studies, 
12 additional ones were excluded: studies without OR or extractable 
data [n = 3], case reports [n = 3], reviews [n = 4], no matching con-
trol group [n = 2, e.g. non-IBD VTE controls]. One additional study 
was excluded from the A-subgroup analysis because of the lack of 
matching controls in the ‘no steroid’ group, although the data of the 
study were eligible for B-subgroup assessment.34 Finally, the remain-
ing eight studies, published between 2012 and 2016, fulfilled the 
selection criteria [Table 1].
3.2. Study characteristics
Eight studies were included in this meta-analysis. Of these, six 
reported on VTE complication in IBD patients during ster-
oid treatment [A-group]20,28–32 and three on anti-TNFα therapy 
[B-group].28,33,34 OR was calculated in CD in one study,29 and in UC 
in two studies,30,31 while the others reported combined CD + UC 
Therapy-specific risk for thrombosis in IBD 491
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results28,32–34; only the publication from Nguyen et al.20assessed VTE 
risk in CD and UC separately. Since the risk for VTE in IBD patients 
is equally increased in both CD and UC, the results of the different 
studies can be evaluated together.8
Statistical analysis was carried out on 40 083 [A-subgroup] and 
18 435 [B-subgroup] IBD patients. In the A-subgroup, 19 645 patients 
had CD and 20 438 had UC. There were 2861 [A-group] and 399 
[B-group] VTE events identified. The mean age ranged from 37.0 to 
45.9 years. Most of the patients included in the studies underwent 
an IBD-related surgery, were hospitalized and were followed during 
hospitalization or up to 3 months after discharge.20,28–30,33 Only a few 
articles reported outcomes retrieved from registries.31,32,34 All of the 
studies were retrospective, including two single-centre and six multi-
centre analyses. The individual study characteristics are provided in 
Tables 2 and 3.
3.3. Risk of VTE in IBD patients treated with 
corticosteroids
Six studies assessed VTE risk in CD and UC patients treated or not 
with systemic corticosteroids.20,28–32 A  total of 40 083 IBD patients 
were analysed and 2861 [7.13%] VTE events were identified as a 
complication. All individual studies had an OR  >  0.989 reaching 
statistical significance [p < 0.05], except the study of Vegh et al. 32 
[p = 0.052]. There was a significantly higher rate of VTE compli-
cations in steroid-treated IBD patients compared to IBD patients 
without steroid medication [OR: 2.202; 95% CI: 1.698–2.856, 
p  <  0.001] [Figure  2]. Evidence of heterogeneity was observed 
[I2 = 66.97; p = 0.006].
3.4. Risk of VTE in IBD patients treated with 
anti-TNFα
Only three studies assessed VTE risk in IBD patients treated with 
anti-TNFα compared to IBD patients treated with systemic corticos-
teroids.28,33,34 A total of 18 435 IBD patients were analysed and 399 
[2.16%] VTE events were reported. Two of three individual stud-
ies had an OR < 1.0 attaining statistical significance [p < 0.05].28,34 
There was a significantly lower rate of VTE complications in anti-
TNFα-treated IBD patients compared to IBD patients with steroid 
medication [OR: 0.267; 95% CI: 0.106–0.674, p = 0.005] [Figure 3], 
with no statistically significant heterogeneity detected across studies 
[I2 = 0.000%, p = 0.476].
3.5. Risk of bias assessment
Overall NOS scores of the included studies in our meta-analysis 
ranged from 5 to 6 [Supplementary Table S4]. Since all studies were 
large IBD cohorts with a corresponding non-exposed control group, 
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they carried a low risk of bias in terms of representativeness, and 
also in terms of ascertainment of exposure. Comparability received 
the lowest count of stars: only 22% of the studies were rated as hav-
ing low risk. All studies provided a clear definition of the diagnosis 
of VTE, including the details of the confirmation based on imaging 
techniques. Some studies used the international disease codes for 
VTE diagnosis. All patients were followed up for at least 3 months, 
thereby fulfilling the corresponding NOS item. Risk of bias of the 
included studies is summarized in Figures 4 and 5.
The funnel plot in Figure  6 shows slight bias potentially as a 
consequence of a ‘small-study effect’, suggesting that smaller trials 
with no or moderate treatment effect may have remained unpub-
lished. In our meta-analysis, the included articles are large cohort 
studies, except for that of Singh et al.,31 where the steroid-user group 
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reflects weight of trial in pooled analysis. Horizontal bars represent 95% confidence intervals.
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included 80 patients. This study may have overestimated the risk of 
VTE, as is well known for small trials.
4. Discussion
Our meta-analysis evaluated pooled data from all currently available 
observational studies evaluating the risk of VTE in IBD as a com-
plication of steroid and anti-TNFα therapies. Our results indicated 
that treatment with anti-TNFα was associated with a significantly 
lower risk of thromboembolic events in IBD patients [OR: 0.267; 
95% CI: 0.106–0.674, p = 0.005] compared to steroid therapy. In 
contrast, VTE in IBD patients using systemic corticosteroids occurs 
twice as often as in the control group of IBD patients without steroid 
medication [OR: 2.202; 95% CI: 1.698–2.856, p < 0.001]. To our 
knowledge, no meta-analysis has evaluated the effect of steroid and 
anti-TNFα treatment in IBD patients. The major strength of our 
meta-analysis is the inclusion of large numbers of IBD patients with 
VTE events analysed at once, which would imply difficulties in ran-
domized controlled trials.
Thromboembolism is one of the extraintestinal manifestations in 
IBD. The prevalence and incidence rate of VTE in IBD are 1.2–6.7% and 
6.3 per 1000 person-years in clinical studies, respectively.15,41,42 DVT and 
PE are the most common types of VTE in IBD, but thromboses may also 
occur at unusual sites such as in cerebrovascular, retinal, portal, mesen-
teric, splenic or internal jugular veins.42,43 The association between VTE 
and disease activity has been well established; at the time of a flare-up, 
the increase in VTE risk is more prominent.14 Other disease-specific risk 
factors, which have been identified in several studies, include colonic 
disease, fistulizing or stenotizing behaviour and surgical treatment.16,44 
Recent literature indicates that drugs used in IBD treatment could also 
be considered as potential contributors to VTE pathogenesis. Systemic 
corticosteroids and anti-TNFα agents are both potent anti-inflammatory 
drugs used in moderately and severely active IBD flare-ups.
Steroids, however, have an independent thrombogenic effect from 
inflammatory processes. It has been shown that exogenous, systemic 
glucocorticoids and also excess endogenous cortisol [e.g. Cushing’s 
syndrome] are linked to VTE risk.45,46 Hypercoagulability in 
Cushing’s syndrome is due to increased production of procoagulant 
factors with activation of the coagulation cascade and an impaired 
fibrinolytic capacity.46 Additionally, the risk of VTE is increased 
among glucocorticoid users in non-IBD populations [for systemic 
glucocorticoids, adjusted incidence rate ratio (IRR) is 2.31, 95% 
CI: 2.18–2.45], and this becomes more prominent at high doses.45,47 
Corticosteroids administered to healthy volunteers also increase 
clotting factor levels and fibrinogen, which may also be related to 
the increased risk of thrombosis in the absence of inflammation.48
TNFα is a proinflammatory cytokine which has been reported to 
link inflammation and thrombosis in IBD. The findings of Yoshida 
et al. implicate TNFα in the enhanced microvascular thrombosis in 
dextran sodium sulphate-induced colitis model, and suggest that the 
action of TNFα accounts for most of the colitis-enhanced throm-
botic response.49 Therefore, patients receiving anti-TNFα agents po-
tentially have a decreased risk for thromboembolic complications. In 
addition to neutralizing TNFα, infliximab treatment in CD signifi-
cantly reduced plasma soluble CD40L inflammatory cytokine levels, 
which might also decrease the risk of VTE.50
During our meta-analysis search, only three studies were found 
assessing VTE risk in IBD patients treated with anti-TNFα agents. 
deFonseka et  al. reported that the VTE risk is significantly lower 
when using TNFα inhibitor therapy in hospitalized IBD patients,28 
whereas systemic corticosteroids were associated with an increased 
risk. In addition, use of anti-TNFα medication lowered the risk of 
post-hospitalization VTE in a greater Boston cohort.33 Higgins et al. 
showed that biologics monotherapy resulted in a 5-fold reduction 
in VTE risk compared with patients receiving corticosteroid treat-
ment.34 Moreover, this association between steroids and VTE risk 
seems to be dose-dependent.34 The study of Higgins et al. showed not 
only that the inflammatory effect itself is responsible for the elevated 
VTE risk in IBD but also that the corticosteroid drugs themselves 
increase VTE risk.34
Several limitations of this meta-analysis must be considered. 
The first is the quality of data. All the included studies have a 
 retrospective design, the data were extracted from medical records 
so patients were not randomized, and unrecognized confounding 
factors could bias our results and weaken the conclusions. At least 
four relevant studies were excluded due to unavailable ORs of VTE 
risk.42,51,52 In the study of Scoville et al.,53 there were non-IBD VTE 
controls as comparators for VTE risk in IBD, which did not match 
the control group criteria in our meta-analysis. Additionally, we can-
not rule out that we lost relevant articles by having imposed English 
language, as a filter, on the search.
Secondly, there was substantial heterogeneity across the studies 
selected in subgroup A [I2 = 66.97]. Very different types of  studies 
were included; some studies are population-based cohorts, while 
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Figure 6. Funnel plot of corticosteroid studies with pseudo 95% confidence limits. Each circle indicates one study with its standard error indicating the weight of 
the study and its relative risk. The dotted lines represent 95% confidence interval to visualize the symmetry around the pooled estimate.
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other data were derived from postoperative settings or hospitalized 
patients. However, the duration of follow-up was almost equal in the 
majority of the included studies. Likewise, there may be variability in 
disease phenotype of IBD among patients. Although colonic disease 
and disease extension correlate with VTE risk,16 the articles included 
no information on disease location or disease characteristics, so we 
were unable to analyse this parameter.
Thirdly, there were no quantitative activity indices for both 
UC and CD available in the publications, although the use of 
steroids and biologics indicates moderate to severe disease course. 
Thus, we could not evaluate the effect of the exact severity of 
the disease and the effect of consecutive immobilization on 
thromboembolic risk.
In addition, we do not know how many IBD patients were given 
pharmacological thromboprophylaxis in the studies. Only two of the 
included studies report on the use of VTE prophylaxis, in which the 
use of thromboembolic prophylaxis based on hospital protocols was 
associated with reduced VTE risk.28,33 However, it is of note that the 
publication year of all trials is mainly before the implementation of 
VTE guidelines and consensus statements.41,54
Finally, if pharmacokinetic measurements had been used in the 
studies, it would have been possible to determine the plausible effect 
of drug levels and anti-drug antibodies on VTE risk.
In summary, the present meta-analysis confirms that cortico-
steroid use in IBD patients carries a 2-fold risk of VTE. In contrast, 
thromboembolic risk decreases when using anti-TNFα agents for 
active disease instead of steroids. These associations highlight the 
importance of steroid-sparing therapy in IBD, especially in patients 
with additional risk factors for VTE. The choice between glucocorti-
coids and anti-TNFα therapy in the management of severe flare-ups 
should take this into consideration, especially in patients with pre-
vious VTE or a family history of thrombotic events.
According to recent guidelines, anticoagulant prophylaxis 
should be considered in all hospitalized and outpatients with se-
vere IBD.41,54,55 Anticoagulant thromboprophylaxis is recommended 
with low-molecular-weight heparin, low-dose unfractioned heparin 
or fondaparinux.41 Recently, a risk assessment algorithm for IBD 
patients at risk of developing VTE has been proposed.56 Patients 
with IBD should be stratified according to their general and IBD-
specific risk factors for VTE into high-risk and intermediate/low-
risk patients. In addition to a detailed patient history focused on 
well-known general and disease-specific VTE risk factors, clot lysis 
parameters should be included in the risk assessment.56 We recognize 
the importance of our findings in the promotion of the appropriate 
thromboprophylaxis during steroid treatment. Further research is 
needed to establish the exact weight of these factors and large pro-
spective cohort studies are awaited.
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